- Conditions
- Anterior Cruciate Ligament Tear
- Interventions
- anakinra (150mg), Saline intraarticularly
- Drug · Other
- Lead sponsor
- Cale Jacobs, PhD
- Other
- Eligibility
- 14 Years to 40 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,512
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Rilpivirine, Placebo
- Drug
- Lead sponsor
- PATH
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Newark, New Jersey • The Bronx, New York
- Conditions
- Epstein-Barr Virus Infection
- Interventions
- mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 34
- States / cities
- Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
- Conditions
- Analgesic Adverse Reaction
- Interventions
- Ketorolac Tromethamine, 0.9% Normal Saline
- Drug
- Lead sponsor
- Albany Medical College
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
- Interventions
- ONCOS-102, Durvalumab, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- San Diego, California • Miami, Florida • Buffalo, New York + 3 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Colorectal Cancer
- Interventions
- panitumumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Arthritis, Rheumatoid
- Interventions
- GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 46
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
- Conditions
- Aging
- Interventions
- Angiotensin-(1-7), Saline
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Wrist Injuries, PRP
- Interventions
- Platelet-rich plasma (PRP)
- Procedure
- Lead sponsor
- Edna Rath
- Federal
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
- Drug
- Lead sponsor
- Epitopoietic Research Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • Boston, Massachusetts
- Conditions
- Acute Intermittent Porphyria
- Interventions
- givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • San Francisco, California • New York, New York + 1 more
- Conditions
- Opioid Use Disorder, Suicidal Ideation
- Interventions
- Ketamine, Saline Solution
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- Aerolized Hydroxychloroquine Sulfate, Placebo
- Drug · Other
- Lead sponsor
- Pulmoquine Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Covid19
- Interventions
- LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 98
- States / cities
- Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
- Conditions
- Post-Traumatic Headache
- Interventions
- AbobotulinumtoxinA, Normal saline
- Drug
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Severe Osteoarthritis of the Knee
- Interventions
- Ampion, Saline
- Biological · Drug
- Lead sponsor
- Ampio Pharmaceuticals. Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,043 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Englewood, Colorado
- Conditions
- HIV Infections
- Interventions
- ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
- Conditions
- Spasticity of the Upper and Lower Limb Due to Cerebral Causes
- Interventions
- IncobotulinumtoxinA
- Drug
- Lead sponsor
- Merz Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Doral, Florida • Indianapolis, Indiana • New York, New York + 3 more
- Conditions
- Breast Cancer, Breast Neoplasm
- Interventions
- Docetaxel - Dose A, Anastrozole, cyclophosphamide, Docetaxel - Dose B, Doxorubicin hydrochloride, Tamoxifen Citrate, Capecitabine - Dose B, Capecitabine - Dose A
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rhinitis + Sinusitis, Pediatric Chronic Rhinosinusitis
- Interventions
- Acclarent Relieva Balloon Sinuplasty, Adenoidectomy + Maxillary Sinus Irrigation
- Device · Procedure
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Surgery
- Interventions
- 0.9% Saline warmed to 37 degrees Celsius, 0.9% Saline warmed to 24 degrees Celsius
- Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- Pregnancy
- Interventions
- Lidocaine, Normal Saline
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois